CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models

Comprehensive molecular portraits of human breast tumours

2012 • 10,753 citations

Triple-Negative Breast Cancer

2010 • 3,588 citations

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

2006 • 3,283 citations

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

2012 • 3,278 citations

Cdks, cyclins and CKIs: roles beyond cell cycle regulation

2013 • 1,325 citations

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

1992 • 1,190 citations

Mechanisms of Endocrine Resistance in Breast Cancer

2010 • 1,087 citations

Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

1994 • 982 citations

Specific protection against breast cancers by cyclin D1 ablation

2001 • 930 citations

Treatment of HER2-positive breast cancer: current status and future perspectives

2011 • 807 citations

Trastuzumab emtansine: mechanisms of action and drug resistance

2014 • 485 citations

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

2010 • 477 citations

Targeted therapies for breast cancer

2011 • 359 citations

Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis

2002 • 339 citations

Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications

2012 • 316 citations

The Requirement for Cyclin D Function in Tumor Maintenance

2012 • 311 citations

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients

2011 • 303 citations

The meaning of p16^ink4aexpression in tumors

2011 • 249 citations

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

2012 • 233 citations

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

2012 • 212 citations

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo

2011 • 211 citations

Targeting the RB-pathway in Cancer Therapy

2010 • 184 citations

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

2013 • 178 citations

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

2012 • 157 citations

A systematic review of dual targeting in HER2-positive breast cancer

2013 • 155 citations

Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer

2011 • 147 citations

Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells

2012 • 140 citations

CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer

2010 • 140 citations

HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer

2011 • 127 citations

Treatment of HER2-overexpressing breast cancer

2010 • 125 citations

Proliferative Suppression by CDK4/6 Inhibition: Complex Function of the Retinoblastoma Pathway in Liver Tissue and Hepatoma Cells

2010 • 122 citations

Targeted Therapy for Breast Cancer

2013 • 115 citations

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

2010 • 114 citations

The Management of Early-Stage and Metastatic Triple-Negative Breast Cancer

2013 • 90 citations

SWI/SNF Deficiency Results in Aberrant Chromatin Organization, Mitotic Failure, and Diminished Proliferative Capacity

2009 • 73 citations

Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff

2014 • 30 citations

The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer

2013 • 25 citations

Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer

2013 • 7 citations

Fifty Years of Systemic Therapy for Breast Cancer: From One Size Fits All to Tailored Therapy

2014 • 2 citations